Your browser doesn't support javascript.
loading
Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers.
Fumagalli, D; Wilson, T R; Salgado, R; Lu, X; Yu, J; O'Brien, C; Walter, K; Huw, L Y; Criscitiello, C; Laios, I; Jose, V; Brown, D N; Rothé, F; Maetens, M; Zardavas, D; Savas, P; Larsimont, D; Piccart-Gebhart, M J; Michiels, S; Lackner, M R; Sotiriou, C; Loi, S.
Afiliação
  • Fumagalli D; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Free University of Bruxelles, Brussels, Belgium.
  • Wilson TR; Oncology Biomarker Development, Genentech Inc., South San Francisco, CA, USA.
  • Salgado R; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Free University of Bruxelles, Brussels, Belgium.
  • Lu X; Department of Biostatistics, Genentech Inc., South San Francisco, CA, USA.
  • Yu J; Department of Biostatistics, Genentech Inc., South San Francisco, CA, USA.
  • O'Brien C; Oncology Biomarker Development, Genentech Inc., South San Francisco, CA, USA.
  • Walter K; Oncology Biomarker Development, Genentech Inc., South San Francisco, CA, USA.
  • Huw LY; Oncology Biomarker Development, Genentech Inc., South San Francisco, CA, USA.
  • Criscitiello C; Division of Early Drug Development for Innovative Therapies, European Institute of Oncology, Milan, Italy.
  • Laios I; Department of Pathology, Institut Jules Bordet, Brussels, Belgium.
  • Jose V; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Free University of Bruxelles, Brussels, Belgium.
  • Brown DN; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Free University of Bruxelles, Brussels, Belgium.
  • Rothé F; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Free University of Bruxelles, Brussels, Belgium.
  • Maetens M; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Free University of Bruxelles, Brussels, Belgium.
  • Zardavas D; Breast International Group, Brussels, Belgium.
  • Savas P; Division of Clinical Medicine and Research, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.
  • Larsimont D; Department of Pathology, Institut Jules Bordet, Brussels, Belgium.
  • Piccart-Gebhart MJ; Division of Medical Oncology, Institut Jules Bordet, Brussels, Belgium.
  • Michiels S; Division of Biostatistics and Epidemiology, Institut Gustave Roussy, Villejuif, France INSERM U1018, CESP, University of Paris, Villejuif, France.
  • Lackner MR; Oncology Biomarker Development, Genentech Inc., South San Francisco, CA, USA.
  • Sotiriou C; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Free University of Bruxelles, Brussels, Belgium Division of Medical Oncology, Institut Jules Bordet, Brussels, Belgium.
  • Loi S; Division of Clinical Medicine and Research, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia sherene.loi@petermac.org.
Ann Oncol ; 27(10): 1860-6, 2016 10.
Article em En | MEDLINE | ID: mdl-27672107
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Receptores de Estrogênio / Indolamina-Pirrol 2,3,-Dioxigenase / Subunidade alfa do Fator 1 Induzível por Hipóxia Tipo de estudo: Prognostic_studies Limite: Female / Humans Idioma: En Revista: Ann Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Bélgica
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Receptores de Estrogênio / Indolamina-Pirrol 2,3,-Dioxigenase / Subunidade alfa do Fator 1 Induzível por Hipóxia Tipo de estudo: Prognostic_studies Limite: Female / Humans Idioma: En Revista: Ann Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Bélgica